Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.56 |
| ▸ | CCR1 | P32246 | 12/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27721784 | 1.00 | NR3C1 (0.56) | NR3C1CCR1SCN9APGRCYP3A4 | |
| SCHEMBL4122908 | 0.86 | NR3C1 (0.65) | NR3C1CCR1PGRCYP3A4CYP2C9 | |
| SCHEMBL4122911 | 0.86 | NR3C1 (0.65) | NR3C1CCR1PGRCYP3A4CYP2C9 | |
| SCHEMBL4784046 | 0.82 | SMO (0.57) | NR3C1PGR | |
| SCHEMBL27721785 | 0.81 | NR3C1 (0.52) | NR3C1CCR1 | |
| Trifluoroacetic Acid SCHEMBL4126266 | 0.77 | NR3C1 (0.53) | NR3C1CCR1 | |
| SCHEMBL4114024 | 0.76 | NR3C1 (0.58) | NR3C1CCR1PGRCYP3A4CYP2C9 | |
| SCHEMBL5137509 | 0.76 | NR3C1 (0.58) | NR3C1CCR1PGRCYP3A4CYP2C9 | |
| SCHEMBL4118844 | 0.74 | NR3C1 (0.50) | NR3C1CCR1 | |
| SCHEMBL4118839 | 0.74 | NR3C1 (0.50) | NR3C1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124607-A1 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| CN-101291914-A | Novel bicyclic sulfonamides for use as glucocorticoid receptor modulators in the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | CN | disclosed |
| EP-1940800-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007046747-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124607-A1 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | NR3C1, NR3C2, MC2R | NR3C1 1/4885CCR1 275/4885SCN9A 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.